Comparison of 2 Preparative Regimens for Stem Cell Transplantation from HLA-Matched Sibling Donors in Patients with Advanced Myelodysplastic Syndrome

Abstract

The objective of this study was to compare how cyclophosphamide (CY) and oral busulfan (BU) therapies, each in combination with total body irradiation (TBI), affect the outcome of stem cell transplantation in patients with advanced myelodysplastic syndrome. This study was conducted with 31 patients who received bone marrow from an HLA-matched sibling and underwent treatment with BU-TBI (n = 18) or CY-TBI (n = 13). The incidence of acute graft-versus-host disease (GVHD) grades II to IV was higher, but not significantly, in the BU-TBI group (58.8%) than in the CY-TBI group (30.8%). However, the incidences of chronic extensive GVHD were significantly different (41.7% [CY-TBI] versus 80.0% [BU-TBI],P =.04). Trends after BU-TBI conditioning indicated a lower 3-year probability of disease-free survival (DFS) (38.1% versus 53.9%,P =.4), lower relapse rates (28.5% versus 36.4%,P =.8), and higher nonrelapse mortality rates (46.7% versus 15.4%,P =.2). After adjusting for the International Prognostic Scoring System risk group and the cytogenetic risk group, DFS in the CY-TBI group (relative risk, 9.0; 95% confidence interval, 1.5–52.5;P =.015) was found to be significantly increased compared with the BU-TBI group. Approaches to minimize transplantation-related toxicity should be pursued, and efforts other than the potentiation of the conditioning regimen should be made to reduce the likelihood of posttransplantation relapse.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologic variants.Semin Hematol. 1996;33:95–110.

    PubMed  CAS  Google Scholar 

  2. 2.

    Jacobs A. Genetic lesions in preleukaemia.Leukemia. 1991;5: 277–282.

    PubMed  CAS  Google Scholar 

  3. 3.

    Mufti GJ, Galton DA. Myelodysplastic syndromes: natural history and features of prognostic importance.Clin Haematol. 1986;15: 953–971.

    CAS  Google Scholar 

  4. 4.

    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes.Br J Haematol. 1982;51: 189–199.

    Article  CAS  Google Scholar 

  5. 5.

    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood. 1997;89:2079–2088.

    PubMed  PubMed Central  CAS  Google Scholar 

  6. 6.

    Pfeilstocker M, Reisner R, Nosslinger T, et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics.Br J Haematol. 1999;106:455–463.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.Leukemia. 1998;12(suppl 1):S25-S29.

    Article  PubMed  Google Scholar 

  8. 8.

    Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.Blood. 2000;95:1188–1194.

    PubMed  CAS  Google Scholar 

  9. 9.

    De Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).Br J Haematol. 2000; 110:620–630.

    Article  Google Scholar 

  10. 10.

    Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle.Blood. 1996;88:358–365.

    PubMed  CAS  Google Scholar 

  11. 11.

    Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation.Blood. 1998; 92:1910–1917.

    PubMed  CAS  Google Scholar 

  12. 12.

    Copelan EA, Penza SL, Elder PJ, et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation.Bone Marrow Transplant. 2000;25:1219–1222.

    Article  PubMed  CAS  Google Scholar 

  13. 13.

    Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy.Blood. 1997;89:2578–2585.

    CAS  Google Scholar 

  14. 14.

    De Witte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG).Br J Haematol. 1990;74:151–155.

    Article  Google Scholar 

  15. 15.

    Niemeyer C, Duffner U, Bender-Gotze C, et al. AML-type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS) [abstract].Blood. 2000; 96(suppl 1):521a.

    Google Scholar 

  16. 16.

    Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.J Clin Oncol. 1996;14:220–226.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. 17.

    Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia.Br J Haematol. 1996;93:59–67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. 18.

    Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.Biol Blood Marrow Transplant. 2002;8:161–169.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.Transplantation. 1974;18:295–304.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. 20.

    Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients.Am J Med. 1980;69:204–217.

    Article  PubMed  CAS  Google Scholar 

  21. 21.

    Karanes C, Abella E, Du W, et al. Allogeneic bone marrow transplantation (alloBMT) in myelodysplastic syndromes (MDS) [abstract].Blood. 1998;92(suppl 1):659a.

    Google Scholar 

  22. 22.

    Horowitz MM. Results of allogeneic stem cell transplantation for malignant disorders. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds.Hematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 2000:1573–1587.

    Google Scholar 

  23. 23.

    Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings.Ann Intern Med. 1983;98:461–466.

    Article  CAS  Google Scholar 

  24. 24.

    Ringden O, Paulin T, Lonnqvist B, Nilsson B. An analysis of factors predisposing for chronic graft-versus-host disease.Exp Hematol. 1985;13:1062–1067.

    PubMed  CAS  Google Scholar 

  25. 25.

    Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.Bone Marrow Transplant. 1991;7:193–198.

    PubMed  CAS  Google Scholar 

  26. 26.

    Carlens S, Ringden O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.Bone Marrow Transplant. 1998;22: 755–761.

    Article  PubMed  CAS  Google Scholar 

  27. 27.

    Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.Blood. 1993;82:677–681.

    PubMed  CAS  Google Scholar 

  28. 28.

    Parker JE, Shafi T, Mijovic A, et al. Allogeneic stem cell transplantation (SCT) in MDS: interim results of outcome following non-myeloablative conditioning compared to standard preparative regimens [abstract].Blood. 2000;96(suppl 1):554a.

    Google Scholar 

  29. 29.

    Kroger N, Schetelig J, Zabelina T, et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.Bone Marrow Transplant. 2001;28: 643–647.

    Article  PubMed  CAS  Google Scholar 

  30. 30.

    Martino R, Caballero MD, Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.Blood. 2002; 100:2243–2245.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. 31.

    Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.Blood. 2002;100:1201–1207.

    Article  PubMed  CAS  Google Scholar 

  32. 32.

    Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.Biol Blood Marrow Transplant. 2002;8: 145–154.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Yoo-Jin Kim or Dong-Wook Kim or Seok Lee or Chang-Ki Min or Dong-Gun Lee or Soo-Mi Choi or Ki-Seong Eom or Hee-Je Kim or Jong-Wook Lee or Woo-Sung Min or Chun-Choo Kim.

About this article

Cite this article

Kim, Y., Kim, D., Lee, S. et al. Comparison of 2 Preparative Regimens for Stem Cell Transplantation from HLA-Matched Sibling Donors in Patients with Advanced Myelodysplastic Syndrome. Int J Hematol 82, 66–71 (2005). https://doi.org/10.1532/IJH97.A30501

Download citation

Key words

  • Myelodysplastic syndrome
  • Stem cell transplantation
  • Busulfan
  • Total body irradiation
  • Cyclophosphamide